Conducting managed access programs presents sizable challenges that must be overcome by biotechnology and pharmaceutical companies to accomplish their essential mission to cure disease and improve the human condition. This infographic highlights just some of the most common challenges inherent in managed access programs and what you need to overcome them.
Most Recent Flipbooks
A lay summary for patients participating in clinical trials
Parexel expert Michelle Pietzak, MD reviews current findings and offers practical recommendations for gastrointestinal symptoms of COVID-19 and considerations for clinical trials.
In this article, experts from the Parexel Pediatric Collaborative Group review current findings and consider how sponsors can adapt their studies to changing conditions during COVID19.
This lay summary discusses what the guidance means for anyone in the USA who may be involved in or associated with a clinical trial.
In this article, Dr. Lazar Mandinov, Sr. Medical Director at Parexel, provides practical guidance for conducting CV clinical trials related to COVID-19.
Updated every day, in a single source
If regulatory and payer landscapes are so different, then why bring the two worlds together?
Parexel offers a complimentary, educational workshop custom built to your evidence and market access needs.